

## GRAND CHALLENGE

#### GC#7410153

# Topic 2 PREVENT: Eliminate or Reduce Urges, Cravings, or Symptoms of Withdrawal

#### THE OPPORTUNITY:

The Ohio Opioid Technology Challenge is a three-phase prize competition that seeks to accelerate the development and deployment of innovative technology solutions that address the opioid crisis through addiction prevention and treatment, and overdose avoidance and response.

The Challenge Phase consists of four Challenge Topics that address specific unmet needs or concerns related to opioid use, abuse and exposure. This Topic seeks solutions that **eliminate or reduce urges, cravings, or symptoms of withdrawal.** 

The Challenge Phase will conclude by awarding <u>up to</u> twelve (12) \$200,000 prizes across the four Topics. Prize Recipients of the Challenge Phase will be eligible to compete in the final, Product Phase of the Challenge with prizes of \$1 million or more.

Submitters must be (i) registered to do business and in good standing in the State of Ohio, or (ii) partnered with an In-State Entity. For purposes of the Challenge Phase, an In-state Entity is an entity that has a substantial presence in Ohio (see ORC 184.10).

#### THE TIMELINE:

Challenge Phase Entry – Due by July 11, 2018 at 5:00 PM EDT Prize Recipients announced September 2018

Visit <a href="www.opioidtechchallenge.com">www.opioidtechchallenge.com</a> to see the other Challenge Topics, see official contest Rules, and submit an entry.

**QUESTIONS:** Contact the Solution Provider Help Desk

Email: <a href="mailto:phd@ninesigma.com">phd@ninesigma.com</a>
Phone: +1-216-283-3901

Ohio



### **Opioid Technology Challenge**

#### **NINESIGMA PROGRAM MANAGER:**

Kevin Andrews, Ph.D.

#### **CHALLENGE DESCRIPTION**

NineSigma, on behalf of the **State of Ohio**, seeks challenge responses which **eliminate or reduce urges**, **cravings**, **or symptoms of withdrawal**.

Responses should be solutions already in development, focused specifically on the Topic. Responses could include but are not limited to: pharmaceuticals, medical devices, or other technologies that reduce cravings and urges or symptoms of withdrawal and offer lasting effects over time.

#### **BACKGROUND**

Opioids are highly addictive and create serious addictive responses within those using them. When an individual finishes a prescription, or when an addicted user seeks recovery, their initial side-effects can be serious. Withdrawal symptoms can include nausea, sleeplessness or restlessness, and agitation. Even individuals who have undergone addiction treatment still fight urges and cravings that can lead to relapse.

This Topic seeks long lasting solutions to better prevent an addictive response from the use of opioids by eliminating or reducing urges, or by better treating the symptoms of withdrawal.

#### MINIMUM REQUIREMENTS FOR ALL CHALLENGE TOPICS:

- Your solution must use technology as a component of your approach including:
  - Sensors, diagnostics, medical devices, pharmaceuticals, and/or health information technology
  - Software, but only if in conjunction with one of the technologies mentioned above
- You must already be working on your approach, have proof of concept, and have compelling data to support the effectiveness of your approach.
- You must have a clear plan and path forward to get your technology ready for broad deployment or implementation.
- Your approach must be able to be implemented in the United States of America (e.g. it should be likely
  to receive regulatory approval) and you must be able to demonstrate your approach in conjunction with
  an Ohio-based entity.
- Your approach must align with one of the four Challenge Topics

#### **APPROACHES THAT DO NOT QUALIFY**

- Approaches that are strictly at early concept stage of development
- Any solution that requires a change in current law, policy, or regulation
- Clinical treatment protocols not associated with a new technology development
- Alternative pain management therapies
- Predictive analytics to inform public policy
- Programs for direct delivery of social or clinical point of care services that do not have a significant technology component
- Education and public awareness programs
- Professional training programs

See Section 8 of the Official Rules for further detail on approaches that do not qualify.

#### **GENERAL EVALUATION CRITERIA FOR ALL CHALLENGE TOPICS:**

Responses should consider:

- How your approach aligns with Key Attributes for the Topic for which you are submitting an Entry
- Technology maturity and time to market
  - For similar approaches, preference will be given to the one that is more mature and/or that has a shorter time to market
- Potential for broad deployment or implementation
- Size/scope of audience impacted ("market size")
- Robustness
- Effectiveness

#### **KEY ATTRIBUTES FOR TOPIC 2 PREVENT:**

Your approach should:

- Reduce urges, cravings, or other symptoms of withdrawal
- · Offer lasting effect/s over time
- Not pose other significant health risks
- Preferably be in a later stage of development
  - o For a pharmaceutical, preferably at least be in human clinical trials
  - o For a medical device, preferably have received 510 (k) clearance

#### **POSSIBLE APPROACHES**

Possible approaches may include, but not be limited to:

• Pharmaceuticals or medical devices that address addictive responses

#### **How to Submit**

You must complete and submit the online response form by July 11, 2018 at 5:00 PM EDT.

Questions in the response form will ask you to provide:	Page Limit
A non-confidential abstract (for public disclosure) in which you summarize your	1
approach and how it addresses prevention, treatment, overdose avoidance, and/or	
overdose response	
A more detailed (preferably non-confidential) description of your approach and its	3
underlying technology. Trade Secrets can be identified in limited circumstances (see	
section 12 of Official Rules for more details).  An explanation of how your approach meets the Key Attributes	1
An estimate of the impact on the opioid crisis—how many people your approach could	1
help	
Rationale of why your approach may be better or more advanced than similar or	1
competing strategies	
A summary of efforts to date and current state of readiness, with evidence and proof of	5
concept. Evidence could include, for example:	
Results of clinical trials	
Animal studies	
Product beta testing	
Peer reviewed research results	
A summary of the steps, resources, and time required to advance your solution to be	4
ready for broad deployment or implementation	
<ul> <li>Explain what you will accomplish during the Product Phase (September 2018-July</li> </ul>	
2019), if awarded in the Challenge Phase. Please discuss how you plan to demonstrate	
your solution.	
<ul> <li>Explain what you will accomplish Post Challenge, if awarded in the Product Phase.</li> </ul>	
Please explain how you will collaborate with Ohio entities or otherwise be present in	
Ohio.	
Description of you and your team	2
Video demonstration [You may also include a video. If you submit a video, it must be in	
one of the following formats: (1) provide a link to a password protected Vimeo video; (2)	
provide a link to an unlisted YouTube video.]	
Uploaded supporting documents (limit of 3, max of 10 MB)	

If you require assistance to submit your response, please contact the Provider Help Desk (phd@ninesigma.com).

#### **ABOUT THIS CHALLENGE**

By submitting a response, you agree to the Official Rules, which include the following requirements:

- You agree to the submission terms described in the response form.
- You agree that your submission does not contain any confidential information (except for information correctly identified as trade secret).
- You are registered to do business and in good standing in the State of Ohio or partnered with an In-State Entity.

•	You acknowledge that sponsor reserves the sole and absolute right and discretion to distribute awards as stated in the contest.
•	To be considered for awards or recognition, submissions must be written in English.